Harbour BioMed, a global biopharmaceutical company, announced that China National Medical Products Administration (NMPA) had approved the investigational new drug (IND) application to commence phase I trial of its B7H4x4-1BB bispecific antibody (HBM7008) in China. This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumour activity of HBM7008 in patients with solid tumours. It has successfully completed the dosing of first patient in the phase I trial of HBM7008 in Australia on 25 May 2022.
HBM7008 is generated from HBM
